Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses

Expert Rev Vaccines. 2016;15(1):119-27. doi: 10.1586/14760584.2016.1105747. Epub 2015 Oct 29.

Abstract

Virus-specific CD8(+) T-cell responses play a major role in the control of HIV replication, and induction of HIV-specific T-cell responses is an important strategy for AIDS vaccine development. Optimization of the delivery system and immunogen would be the key for the development of an effective T cell-based AIDS vaccine. Heterologous prime-boost vaccine regimens using multiple viral vectors are a promising protocol for efficient induction of HIV-specific T-cell responses, and the development of a variety of potent viral vectors have been attempted. This review describes the current progress of the development of T cell-based AIDS vaccines using viral vectors, focusing on Sendai virus vectors, whose phase I clinical trials have been performed.

Keywords: AIDS vaccine; CTL; HIV; SIV; Sendai virus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / administration & dosage
  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology*
  • AIDS Vaccines / isolation & purification
  • CD8-Positive T-Lymphocytes / immunology*
  • Drug Carriers*
  • Drug Discovery / methods
  • Drug Discovery / trends
  • Genetic Vectors*
  • Humans
  • Sendai virus / genetics*
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology
  • Vaccines, Synthetic / isolation & purification

Substances

  • AIDS Vaccines
  • Drug Carriers
  • Vaccines, Synthetic